JNJ-77242113
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | |
JNJ-77242113 is an experimental peptide and orally administered interleukin-23 receptor antagonist that was developed to treat psoriasis.[1][2][3][4]
References[edit]
- ^ Rusiñol, Lluís; Carmona-Rocha, Elena; Puig, Lluís (3 July 2023). "Psoriasis: a focus on upcoming oral formulations". Expert Opinion on Investigational Drugs. 32 (7): 583–600. doi:10.1080/13543784.2023.2242767. PMID 37507233. S2CID 260286273.
- ^ Fourie, Anne; Cheng, Xiaoli; Chang, Leon; Greving, Carrie; Patrick, Aaron; Knight, Beverly; Polidori, David; Patch, Raymond; Bhandari, Ashok; Liu, David; Huie, Keith; Li, Shu; Rodriguez, Michael; Kannan, Arun; Sherlock, Jonathan; Modi, Nishit (October 2023). "S1028 Characterization of a First-in-Class Oral Therapy Selectively Targeting the IL-23 Pathway". American Journal of Gastroenterology. 118 (10S): S781. doi:10.14309/01.ajg.0000953752.29003.56.
- ^ Ghusn, Wissam; Gala, Khushboo; Rahme, Serena Joseph; Salame, Marita; Mrad, Rudy; Abboud, Donna Maria; Tariq, Raseen; Acosta, Andres; Chedid, Victor (October 2023). "S1029 Disparities in Age, Sex, Race, and Ethnicity in Clinical Trials Focused on Inflammatory Bowel Disease in the United States". American Journal of Gastroenterology. 118 (10S): S781–S782. doi:10.14309/01.ajg.0000953756.85659.9e.
- ^ Brayden, David J. (November 2022). "Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials". BioDrugs. 36 (6): 687–700. doi:10.1007/s40259-022-00562-6. PMID 36282433. S2CID 253109130.